25 July 2022

---

RXDATA and EDRA enter into a long-term partnership

New York, 19 July 2022. RxData, Inc. has entered into a long-term partnership with Edra US, cementing its status as a key player within the pharmaceutical global market access and pricing space.

---

New York, 19 July 2022. RxData, Inc. has entered into a long-term partnership with Edra US, cementing its status as a key player within the pharmaceutical global market access and pricing space.

Edra is a leader in communication, information and training addressed to health professionals, via products (magazines, books, manuals, publications) and services (training courses, events, databases, and e-solutions), either on paper or in digital form. Edra S.p.A. owns the Codifa® and Informatore Farmaceutico® brands, gold standard repositories of drug information. Edra currently employs over 600 highly qualified professionals spanning across its 8 office locations and operates in 60+ countries.

“Edra completely aligns with and understands our long-term vision of capitalizing on an ever-growing dataset of market access and pricing decisions. We wanted to partner with a player which would understand our careful and step approach to building what is now an industry-leading dataset. We have never demurred from this goal since 2014 and are thrilled to have reached this milestone with a prestigious international group of the caliber of Edra,” comments Lawrence Monoson, CEO RxData.

“Thanks to the partnership with RxData, our group is significantly bolstering its North American presence,” comments Giorgio Albonetti, President LSWR Group, Edra’s holding company. “RxData’s foothold within the U.S. life sciences industry and its industry-leading expertise within pharma pricing and market access were strong drivers of this partnership which we intend to develop over the many years to come,” concludes Tommaso Albonetti, General Manager of Edra US.

PR Contacts:

Edra Us | info@edrapublishing.com | (415) 424 2162

RxData | info@rxdata.net | (646) 427 4465